Patents by Inventor James N. KOCHENDERFER

James N. KOCHENDERFER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11236161
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20210363245
    Abstract: An embodiment of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: September 17, 2019
    Publication date: November 25, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Shicheng Yang
  • Publication number: 20210260125
    Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: June 26, 2019
    Publication date: August 26, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Steven A. Feldman
  • Patent number: 11066674
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: July 20, 2021
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20210123063
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 29, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20210095294
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 1, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20210095295
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 1, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10900042
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: January 26, 2021
    Assignee: The United States of Americans, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10876123
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: December 29, 2020
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10844387
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 24, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10837019
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: November 17, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10829769
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: November 10, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10829768
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: November 10, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10829767
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 10, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10815301
    Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD30 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed. Methods of treating or preventing a condition in a mammal, wherein the condition is cancer, are also disclosed.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: October 27, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Service
    Inventor: James N. Kochenderfer
  • Patent number: 10815488
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: October 27, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10815487
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: October 27, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10767184
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 8, 2020
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10738312
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: August 11, 2020
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10738313
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: August 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer